Single injection of Alnylam's RNAi therapy reduces Alzheimer's-linked proteins by 65% for six months
A single injection of an experimental treatment for Alzheimer’s reduced levels of proteins linked to the disease by roughly two-thirds for six months, Alnylam announced Monday at a medical meeting.
But the next part of the ongoing study, which will test repeated administration of the drug, remains on a partial clinical hold in the US. That hold is because of “findings in non-human primate toxicology studies, which were done at very high doses and high exposures,” Pushkal Garg, Alnylam’s chief medical officer, told Endpoints News in an interview. “We are working through that with the regulators.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
